[HTML][HTML] Targeting CD22 for B-cell hematologic malignancies
J Xu, W Luo, C Li, H Mei - Experimental Hematology & Oncology, 2023 - Springer
CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
[HTML][HTML] Targeting CD22 for B-cell hematologic malignancies
J Xu, W Luo, C Li, H Mei - Experimental Hematology & Oncology, 2023 - ncbi.nlm.nih.gov
CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
Targeting CD22 for B-cell hematologic malignancies
J Xu, W Luo, C Li, H Mei - Experimental Hematology & …, 2023 - search.proquest.com
CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
[HTML][HTML] Targeting CD22 for B-cell hematologic malignancies
J Xu, W Luo, C Li, H Mei - Experimental …, 2023 - ehoonline.biomedcentral.com
CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
Targeting CD22 for B-cell hematologic malignancies
J Xu, W Luo, C Li, H Mei - Experimental hematology & …, 2023 - pubmed.ncbi.nlm.nih.gov
CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
Targeting CD22 for B-cell hematologic malignancies.
J Xu, W Luo, C Li, H Mei - Experimental Hematology & Oncology, 2023 - europepmc.org
CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
[PDF][PDF] Targeting CD22 for B-cell hematologic malignancies
J Xu, W Luo, C Li, H Mei - 2023 - ehoonline.biomedcentral.com
CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
Targeting CD22 for B-cell hematologic malignancies.
J Xu, W Luo, C Li, H Mei - Experimental Hematology & Oncology, 2023 - europepmc.org
CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …